Difference between revisions of "Talk:Assessment of the health impacts of H1N1 vaccination/Group C"
From Testiwiki
Jpmannikko (talk | contribs) (→Pandemrix should not be used because of narcolepsy risk) |
Jpmannikko (talk | contribs) (→Pandemrix should not be used because of narcolepsy risk) |
||
| Line 12: | Line 12: | ||
{{defend|2 |The reputation of Pandemrix is globally so poor that it is impossible to use it any more.|--[[User:Jouni|Jouni]] 23:05, 31 March 2011 (EEST)}} | {{defend|2 |The reputation of Pandemrix is globally so poor that it is impossible to use it any more.|--[[User:Jouni|Jouni]] 23:05, 31 March 2011 (EEST)}} | ||
:{{defend|3 |In Finland, THL decided to stop the use of Pandemrix.|--[[User:Jouni|Jouni]] 23:05, 31 March 2011 (EEST), [http://www.thl.fi/fi_FI/web/fi/uutinen?id{{eq}}22930]}} | :{{defend|3 |In Finland, THL decided to stop the use of Pandemrix.|--[[User:Jouni|Jouni]] 23:05, 31 March 2011 (EEST), [http://www.thl.fi/fi_FI/web/fi/uutinen?id{{eq}}22930]}} | ||
| − | {{defend| | + | ::{{attack|4 |Kari Välimäki, Chief of staff at the Ministry of Social Affairs and Health argues, that the suspension of Pandemrix is only a precautionary action, and that there is no doubt that in a similar situation, the same decisions would have been made.|--[[User:Jpmannikko|Jpmannikko]] 16:55, 4 April 2011 (EEST)}} |
| − | :{{attack| | + | {{defend|5 |There have been claims that THL would have had a conflict of interest, as it had received financing worth EUR 6 million from the vaccine producer GalaxoSmithKline (GSK)|--[[User:Jpmannikko|Jpmannikko]] 16:51, 4 April 2011 (EEST)}} |
| + | :{{attack|6 |The World Health Organization (WHO) examined the link between THL and GSK and found no evidence that research funding and the pharmaceutical company would have influenced the choise of vaccines|--[[User:Jpmannikko|Jpmannikko]] 16:51, 4 April 2011 (EEST)}} | ||
}} | }} | ||
Revision as of 13:55, 4 April 2011
Pandemrix should not be used because of narcolepsy risk
Jukka-Pekka?, Kati?
| Statements: Pandemrix should not be used any more anywhere because its narcolepsy risk is too high. NOTE! The time of the statement is September 2010.
Resolution: Resolution not yet found. (A stable resolution, when found, should be updated to the main page.) |
| Argumentation:
⇤1 : Despite risks, Pandemrix is an effective vaccine and has clearly net positive effects in countries where emergency treatment is poorly available for severe swine flu cases. --Jouni 23:05, 31 March 2011 (EEST) ←2 : The reputation of Pandemrix is globally so poor that it is impossible to use it any more. --Jouni 23:05, 31 March 2011 (EEST)
←5 : There have been claims that THL would have had a conflict of interest, as it had received financing worth EUR 6 million from the vaccine producer GalaxoSmithKline (GSK) --Jpmannikko 16:51, 4 April 2011 (EEST)
|
